DocMorris AG (ZRSEF) Q2 2025 Earnings Call Transcript

DocMorris AG (ZRSEF) reported robust H1 2025 performance, with Rx business revenue up 43.5% and TeleClinic surging over 150%, bolstered by the reconfirmed German Rx bonus and AI initiatives like the DocMorris Health Companion. The company successfully completed a CHF 200 million capital increase with a 99% take-up rate, underscoring strong investor confidence. DocMorris reconfirmed its full-year guidance for over 10% revenue growth and an EBITDA loss of CHF 35-55 million, signaling steady core business expansion, rapid scaling of new value drivers, and solid financial positioning.

Analysis

DocMorris AG reported a strong first half for 2025, driven by exceptional growth in its high-potential segments. The core prescription (Rx) business revenue expanded by a robust 43.5%, a performance reinforced by the reconfirmation of the German Rx bonus which solidifies its competitive positioning. The TeleClinic segment demonstrated hyper-growth, with revenues surging over 150% year-on-year, indicating successful scaling of new value drivers. While the non-Rx business posted more modest growth at 4.4%, it was noted as steady and profitable. Financially, the company's position was significantly strengthened by a successful CHF 200 million capital increase, which saw a 99% take-up rate, signaling very strong shareholder confidence. Despite this top-line momentum, the company confirmed its full-year guidance for an adjusted EBITDA loss between CHF 35 million and CHF 55 million, alongside revenue growth expectations of over 10%, indicating that investments in growth, such as the new AI-powered Health Companion, continue to precede profitability.

Key Decisions for Investors

• Investors should recognize the strong validation of the company's growth strategy, evidenced by the high take-up rate of the capital increase and the significant revenue acceleration in the Rx and TeleClinic businesses.
• Monitor the company's cash burn and progress toward the guided EBITDA range, as the path to profitability remains a key risk factor despite the secured funding.
• The rollout and user adoption of the AI Health Companion and the continued scaling of TeleClinic are critical long-term catalysts to watch, as they represent the main drivers for future value creation beyond the traditional pharmacy model.
• Given the importance of the German Rx bonus to the company's competitive advantage, any future regulatory discussions or changes in that market should be considered a key factor for the investment thesis.